The androgen receptor (AR) and its signaling pathway play an important role in the development and progression of prostate cancer (PCa).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
In the setting of primary treatment of PCa with radiotherapy (RT), where the AR can be expected to be of more importance, studies evaluating the AR expression are lacking. The goal of this research is to evaluate AR protein expression in hormone-naive PCa patients treated by RT and investigate its possible prognostic role. Primary biopsy samples of 18 patients treated with primary RT were analyzed including the corresponding clinical information. AR protein expression of the tumor epithelium (with highest Gleason pattern) and the surrounding stroma was quantified using the Quick score for steroid receptors. The differential expression between epithelium and stroma, respectively, between tumor and normal tissue (ΔTumor - ΔBenign >2 versus ≤ 2), was predictive for clinical progression-free survival in the biopsy samples (P = 0.014). Preliminary results of this research show already a promising role of differential AR expression in predicting clinical relapse after PCa treatment with primary EBRT. Further research is needed to validate these findings. Hopefully this can lead to a better understanding of PCa evolution and eventually lead to better therapy strategies.
Poelaert F, Van Praet C, Beerens AS, De Meerleer G, Fonteyne V, Ost P, Lumen N. Are you the author?
Department of Urology, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium; Department of Pathology, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium; Department of Radiotherapy Oncology, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium.
Reference: Biomed Res Int. 2015;2015:812815.